Bone matters in lung cancer

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2215-2222

  Brodowicz, T ^a   O'byrne, K ^b   Manegold, C ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bone metastases; Lung neoplasms; Neoplasm metastases; Quality of life; Skeletal related events

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; DENOSUMAB; GEFITINIB; MITOMYCIN C; PLACEBO; VINBLASTINE; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; JAW OSTEONECROSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SPINAL CORD METASTASIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84865536157     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds009     Document Type: Review

References (69)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr (29 November 2011, date last accessed).
2. Brenner H, Francisci S, de Angelis R et al. ng-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 2009; 45: 1028-1041.
3. D'Addario G, Fruh M, Reck M et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21Suppl 5v116-v119.
4. Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer 2006; 7Suppl 4S111-S117.
5. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
6. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
8. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
9. Zhou C, Wu Y-L, Chen G et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010; 21 Suppl 8: viii6 (Abstr LBA13).
10. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
11. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
12. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
13. Fuller K, Wong B, Fox S et al. TRANCE is necessary and sufficient for osteoblastmediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
14. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
15. Lacey DL, Tan HL, Lu J et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157: 435-448.
16. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066.
17. Lipton A, Steger GG, Figueroa J et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14: 6690-6696.
18. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
19. Body JJ, Lipton A, Gralow J et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 25: 440-446.
20. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
21. Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic significance of micrometastases in non-small-cell lung cancer. Clin Lung Cancer 2004; 5: 214-225.
22. Di Maio M, Gridelli C, Gallo C et al. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer 2004; 90: 2288-2296.
23. Pockett RD, Castellano D, McEwan P et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010; 19: 755-760.
24. Iordanidou L, Trivizaki E, Saranti S et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J BUON 2006; 11: 491-497.
25. Cheran SK, Herndon JE, II, Patz EF, Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44: 317-325.
26. MacManus MP, Hicks RJ, Matthews JP et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287-293.
27. Irving L. Detection of bone metastases in non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22: 7189 (Abstr 7189).
28. Rosen LS, Gordon D, Tchekmedyian NS et al. ng-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, doubleblind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
29. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-3157.
30. Sekine I, Nokihara H, Yamamoto N et al. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 2009; 65: 219-222.
31. Sun JM, Ahn JS, Lee S et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 2011; 71: 89-93.
32. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57: 229-232.
33. Jaukovic L, Ajdinovic B, Jankovic Z, Dugonjic S. Incidence and imaging characteristics of skeletal metastases detected by bone scintigraphy in lung cancer patients. Vojnosanit Pregl 2006; 63: 1001-1005 (Article in Serbian).
34. Hirsh V, Tchekmedyian NS, Rosen LS et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6: 170-174.
35. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
36. Welshman A. Palliative care. Some organisational considerations. Minerva Anestesiol 2005; 71: 439-443.
37. Costa L, Badia X, Chow E et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008; 16: 879-889.
38. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-1594.
39. Rustoen T, Moum T, Padilla G et al. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 2005; 30: 234-242.
40. Ferrell BR, Ferrell BA, Rhiner M, Grant M. Family factors influencing cancer pain management. Postgrad Med J 1991; 67 Suppl 2: S64-S69.
41. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007; 109: 2334-2342.
42. Delea T, Langer C, McKiernan J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67: 390-396.
43. Delea T, McKiernan J, Brandman J et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4: 341-347.
44. Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997; 12: 2478-2480.
45. de Jongh FE, van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-1206.
46. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
47. Abramson EC, Chang J, Mayer M et al. Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption. J Bone Miner Res 1988; 3: 541-546.
48. Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium 2008; 18: 527-533 (Article in Japanese).
49. Otsuka S, Hanibuchi M, Ikuta K et al. A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncol Res 2009; 17: 581-591.
50. Kolaczkowska M, Junik R, Rzymkowska M, Kramer L. The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer. Pneumonol Alergol Pol 1998; 66: 283-289 (Article in Polish).
51. Zukawa M, Nakano M, Hirano N et al. The effectiveness of gefitinib on spinal metastases of lung cancer-report of two cases. Asian Spine J 2008; 2: 109-113.
52. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
53. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Non-small cell lung cancer (version 3.2011). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (27 June 2011, date last accessed).
54. De Marinis F, Eberhardt W, Harper PG et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009; 4: 1280-1288.
55. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082-1090.
56. Saad F, Gleason DM, Murray R et al. ng-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
57. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3: CD003474.
58. Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 306-312.
59. European Medicines Agency. Zometa® (Zoledronic Acid): Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/000336/WC500051730.pdf (21 November 2011, date last accessed).
60. Hu XY, Zou QF, Jin C et al. Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 1343-1346 (Article in Chinese).
61. Calderone RG, Nimako K, Leary AN et al. Use of zoledronic acid in lung cancer. J Thor Oncol 2010; 5: S99-100 (Abstr 253P).
62. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010; 86: 421-435.
63. Gebara SN, Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm 2009; 66: 1541-1547.
64. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007; 5: 475-482.
65. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679.
66. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
67. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
68. Jones DH, Nakashima T, Sanchez OH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-696.
69. Scagliotti G, Hirsh V, Siena S et al. Overall survival improvement in patients with lung cancer treated with denosumab versus zoledronic acid: results from a randomized phase 3 study. Presented at: 14th World Congress on Lung Cancer, July 2011, Amsterdam, The Netherlands. http://www.2011worldlungcancer.org/abstracts.html (27 June 2011, date last accessed).